scispace - formally typeset
Journal ArticleDOI

Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats.

Alok Nahata, +1 more
- 01 May 2012 - 
- Vol. 44, pp 396-409
TLDR
UD can be used as an effective drug for the management of BPH, and histological examinations carried out on prostates from each group led to this conclusion.
Abstract
The present study investigated the effects of stinging nettle (Urtica dioica L.) (UD) on benign prostatic hyperplasia (BPH) induced by testosterone. In vitro studies were conducted to assess the 5α-reductase inhibitory potential of UD. Two biochemical markers viz., β-sitosterol and scopoletin, were isolated and characterised in the extracts utilising High-performance thin layer chromatographic, FTIR, NMR and overlain UV spectral studies. Hyperplasia was induced in rats by subcutaneous administration of testosterone (3 mg kg(-1) s.c.) for 28 days in all the groups except the vehicle-treated group. Simultaneous administration of petroleum ether and ethanolic extracts (10, 20 and 50 mg kg(-1) p.o.) and isolated β-sitosterol (10 and 20 mg kg(-1) p.o.) was undertaken. Finasteride was used as a positive control (1 mg kg(-1) p.o.). Measurement of prostate/body weight ratio, weekly urine output and serum testosterone levels, prostate-specific antigen levels (on day 28) and histological examinations carried out on prostates from each group led us to conclude that UD can be used as an effective drug for the management of BPH.

read more

Citations
More filters
Journal ArticleDOI

Phytochemical, phylogenetic, and anti-inflammatory evaluation of 43 Urtica accessions (stinging nettle) based on UPLC-Q-TOF-MS metabolomic profiles.

TL;DR: Anti-inflammatory in vitro COX1 enzyme inhibition assays suggest that bioactivity may be predicted by gross metabolic profiling in Urtica, and principal component analysis and hierarchical clustering analysis provides a first structured chemotaxonomy of the genus.
Journal ArticleDOI

What do we know about phytotherapy of benign prostatic hyperplasia

TL;DR: Clinical trials indicate significant efficacy in improving urinary symptoms and mild adverse effects for some phytotherapeutic agents, while further clinical evidence is needed for others (e.g., Epilobium spp., Secale cereale, Roystonea regia).
Journal Article

Total Phenolic and Flavonoid Contents of Aqueous Extract of Stinging Nettle and In Vitro Antiproliferative Effect on Hela and BT-474 Cell Lines

TL;DR: Although the relatively high amount of phenolic and flavonoid contents of the aqueous extract of Stinging nettle make this plant a promising candidate for diseases treatment; however, there is not a direct relationship between the amounts of these antioxidant components and the efficiency in in vitro cancer treatment.
Journal ArticleDOI

Screening of pharmacological uses of Urtica dioica and others benefits.

TL;DR: The nettle is actually a plant with many qualities and uses, and the interest in it is deserved and it is given by other studies and investigations.
Journal ArticleDOI

Phytochemistry and pharmacologic properties of Urtica dioica L.

TL;DR: This paper presents comprehensive analyzed information on the botanical, chemical and pharmacological aspects of U. dioica, which has been shown to have antibacterial, antioxidant, analgesic, anti-inflammatory, antiviral,Anti-colitis, anticancer and anti-Alzheimer activities.
References
More filters
Journal ArticleDOI

Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.

TL;DR: Measurement of percentage of free PSA in serum improves specificity of prostate cancer screening in selected men with elevated total serum PSA levels and can reduce unnecessary prostate biopsies with minimal effects on the cancer detection rate; however, further studies are needed to define optimal cutoffs.
Journal ArticleDOI

Saw Palmetto Extracts for Treatment of Benign Prostatic Hyperplasia: A Systematic Review

TL;DR: The evidence suggests that S repens improves urologic symptoms and flow measures and was associated with fewer adverse treatment events in men with symptomatic benign prostatic hyperplasia.
Journal ArticleDOI

Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia

TL;DR: Significant improvement in symptoms and urinary flow parameters show the effectiveness of beta-sitosterol in the treatment of benign prostatic hyperplasia.
Journal ArticleDOI

5α-reductase activity in the prostate

TL;DR: Clinical trials are under way using new drugs, such as GI-198745 (Glaxo-Wellcome, Research Triangle Park, NC), PNU 157706 (Pharmacia & Upjohn, Peapack, NJ), FR146687 (Fujisawa, Osaka, Japan), and LY 320236 (Lilly, Indianapolis, IN), which inhibit both the type-1 and type-2 5alpha-reductase.
Related Papers (5)